Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

PIONEER · Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope

H2020Status: CLOSED1 May 201831 October 2023EU funding €6,000,000Call H2020-JTI-IMI2-2016-10-two-stage

Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such as insufficient knowledge on risk factors that contribute to PCa and on patient characteristics (including genetic profiles) that could facilitate patient stratification. Finally, there is lack of meaningful engagement of all key stakeholders, while the knowledge currently gained from clinical practice and real life data is not being fed back into PCa patients’ care pathways. There is thus a need for better definition of PCa across all stages, improved patient’s stratification at diagnosis, and standardisation of PCa-related outcomes based on real life data.PIONEER’s unique dual approach is to first identify critical evidence gaps in PCa by respected Key Opinion Leaders, and then embark on a research priority setting exercise that reflects the needs of all key stakeholders in PCa management. To achieve this, PIONEER has brought together comprehensive datasets that consists of the most relevant prostate clinical trials and registries, large epidemiological cohorts, electronic heath records, and real-life data from different European (and non-European) patient populations. These unique data sets will be integrated, standardised, harmonised and analysed using approaches that are built on our experience of similar previous IMI projects i.e EMIF, and eTRIKS, and analysed using a unique set of methodologies and advanced analytics methods (OMOP, eHS). PIONEER has already performed a first PCa research priority setting survey, where major stakeholders were asked to identify the current unmet needs in PCa. The five most important open questions will be used as pilot studies to verify PIONEER’s research framework. As such, PIONEER’s deliverables will be outcome-driven, value-based and patient-centric, and relevant to all key stakeholders, as they would have been meaningfully involved from the inception of the project.

Consortium · 34 organisations

coordinator

STICHTING EUROPEAN UROLOGICAL FOUNDATION

NL · €797,439

participant

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

UK · €409,303

participant

NV SAS INSTITUTE SA

BE

participant

PNO Life Sciences & Health B.V.

NL · €237,500

participant

INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD

UK · €31,250

participant

European Alliance for Personalised Medicine

SI · €180,000

participant

LUNDS UNIVERSITET

SE · €185,761

participant

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

UK · €200,000

participant

WEIZMANN INSTITUTE OF SCIENCE

IL · €200,000

participant

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

BE · €16,000

participant

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €125,000

participant

ASTRAZENECA AB

SE

participant

THE ECANCER GLOBAL FOUNDATION

UK · €37,333

participant

IHE, INSTITUTET FOR HALSO- OCH SJUKVARDSEKONOMI AKTIEBOLAG

SE · €175,000

participant

ORION OYJ

FI

participant

THE HYVE BV

NL · €400,000

participant

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM

NL · €124,922

participant

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

UK

participant

TAMPEREEN KORKEAKOULUSAATIO SR

FI · €212,500

participant

ASTELLAS PHARMA EUROPE BV

NL

participant

EUROPEAN CANCER PATIENT COALITION

BE · €69,994

participant

PINSENT MASONS LLP

UK · €188,800

participant

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

DE · €150,000

participant

BAYER AKTIENGESELLSCHAFT

DE

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €415,349

participant

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

FR

participant

ASSOCIATION EISBM

FR · €758,200

participant

GOETEBORGS UNIVERSITET

SE · €150,650

participant

HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV

DE · €101,300

participant

LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED

UK

participant

JANSSEN PHARMACEUTICA NV

BE

participant

KING'S COLLEGE LONDON

UK · €359,000

participant

UNIVERSITA VITA-SALUTE SAN RAFFAELE

IT · €312,500

participant

TECHNISCHE UNIVERSITAET DRESDEN

DE · €125,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.